About
Targeting allosteric mutant oncogenes
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
291
By Phase
PHASE1/PHASE2: 1PHASE1: 1
By Status
ACTIVE_NOT_RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT05256290Lead Sponsor
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
PHASE1/PHASE2Active, not recruiting
200 participants
Started: Mar 31, 2022 · Completed: Jun 30, 2026
NCT04209465Lead Sponsor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
PHASE1Terminated
91 participants
Started: Dec 19, 2019 · Completed: Sep 16, 2022
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...